Is ruxolitinib cream launched in China?

Ruxolitinib cream, as a skin disease treatment drug with significant efficacy, has been widely used and recognized abroad. However, in our country, this drug is not yet on the market, and therefore it is not included in the medical insurance system.

Ruxolitinib cream has not yet received marketing approval in my country. This may be due to various reasons such as drug introduction, approval process, clinical trials, etc. Although the drug has shown significant efficacy in treating vitiligo and other skin diseases abroad, in my country, it still needs to go through a series of strict approval procedures to ensure its safety and effectiveness before it can be marketed.

Since ruxolitinib cream is not yet on the market in my country, it is naturally not included in the scope of medical insurance. The medical insurance drug list usually includes drugs that are already on the market and have been evaluated to have clinical value, safety and effectiveness. Therefore, only after ruxolitinib cream is officially launched on the market, can it be included in the medical insurance catalog after evaluation.

The absence of ruxolitinib cream is undoubtedly a pity for patients with vitiligo and other skin diseases in my country. This drug has proven its efficacy abroad and is of great significance in improving patients' quality of life. We hope that relevant departments can speed up the approval process and introduce more innovative drugs to meet the needs of patients.

The introduction and launch of drugs is not an overnight process and requires efforts and cooperation from many aspects. All parties, including pharmaceutical companies, regulatory agencies, and medical institutions, should work together to promote the development and launch of innovative drugs and provide patients with more treatment options.